Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs HP Inc (HPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs HP Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while HP Inc trades at $24.19 (market cap $22.15B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and HP Inc pays a 4.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HPQ | |
|---|---|---|
Market Cap | $39.89B | $22.15B |
Sector | Health | Technology |
52-Week High | $491.22 | $29.35 |
52-Week Low | $278.09 | $18.20 |
Enterprise Value | $38.15B | $29.31B |
Dividend Yield | — | 4.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HPQ trades at $24.22, up 0.37% today, with a bullish technical outlook and strong recent earnings beats. The stock shows attractive valuation with a P/E of 8.97 and P/S of 0.4, supported by consistent operating cash flow of $3.7B in 2025. Recent news highlights HP's AI PC partnerships and dividend yield near 5%, though revenue growth remains modest amid industry headwinds.
Outlook is cautiously positive given low valuation and dividend appeal, but risks include PC market volatility and competitive pressures. Analyst consensus is mixed with a $22 price target below current levels, suggesting limited near-term upside despite fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
